top of page

Home
About Us
Family Support
NTG-EDSD
Education
Webinars
Events
Contact Us
Publications
Resources
Projects

NTG News

All Posts
Pharmaceutical
Down Syndrome
NTG-EDSD
COVID-19
Education
Clinical
International
NTG Activities
Family Support
Autism
Developmental Disabilities
Policy and Advocacy
Diagnostics

Search

FDA Approves use of Leqembi for Alzheimer's

Jan 7
1 min

FDA Approves use of Leqembi for Alzheimer's

Closure on Biogen's Aduhelm Launch - Congressional Report

Jan 3
1 min

Closure on Biogen's Aduhelm Launch - Congressional Report

ENACT Act Will Help with Inclusion in Clinical Trials

Dec 20, 2022
1 min

ENACT Act Will Help with Inclusion in Clinical Trials

Biogen announces positive results for Alzheimer's drug Lecanemab

Dec 6, 2022
1 min

Biogen announces positive results for Alzheimer's drug Lecanemab

Disappointing Results from Amyloid Reducing Drug Trial

Jun 20, 2022
1 min

Disappointing Results from Amyloid Reducing Drug Trial

untitled image

Oct 8, 2021
1 min

NTG Video on Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer's Disease

National Task Group on Intellectual Disabilities and Dementia Practices

Not-for-profit Corporation | EIN 85-2663072

Mailing Address: PO Box 862, Rockport, ME 04856 USA

Accessibility Statement

Board Members Login

Affiliated Regional Trainers

Affiliated Provincial Trainers

© 2023 by National Task Group on Intellectual Disabilities and Dementia Practices

Last updated 12/7/2023

bottom of page